Serum matrix metalloproteinase levels in polymyositis/dermatomyositis patients with interstitial lung disease
-
- Yoshinari Nakatsuka
- Department of Respiratory Care and Sleep Medicine
-
- Tomohiro Handa
- Department of Advanced Medicine for Respiratory Failure
-
- Ran Nakashima
- Department of Rheumatology and Clinical Immunology
-
- Kiminobu Tanizawa
- Department of Respiratory Medicine
-
- Takeshi Kubo
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto
-
- Yuko Murase
- Department of Respiratory Medicine
-
- Akihiko Sokai
- Department of Respiratory Medicine, Takatsuki Red Cross Hospital, Osaka
-
- Kohei Ikezoe
- Department of Respiratory Medicine
-
- Yuji Hosono
- Department of Rheumatology and Clinical Immunology
-
- Kizuku Watanabe
- Department of Respiratory Medicine
-
- Shinsaku Tokuda
- Department of Respiratory Medicine
-
- Kazuko Uno
- Louis Pasteur Center for Medical Research, Kyoto
-
- Akihiko Yoshizawa
- Department of Diagnostic Pathology
-
- Tatsuaki Tsuruyama
- Department of Drug and Discovery Medicine
-
- Ryuji Uozumi
- Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto
-
- Sonoko Nagai
- Kyoto Central Clinic Clinical Research Center, Kyoto
-
- Kazuhiro Hatta
- Department of Rheumatology
-
- Yoshio Taguchi
- Department of Respiratory Medicine, Tenri Hospital, Nara
-
- Michiaki Mishima
- Saiseikai Noe Hospital, Osaka, Japan
-
- Kazuo Chin
- Department of Respiratory Care and Sleep Medicine
-
- Tsuneyo Mimori
- Department of Rheumatology and Clinical Immunology
-
- Toyohiro Hirai
- Department of Respiratory Medicine
説明
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Objective</jats:title> <jats:p>We aimed to clarify the clinical significance of serum levels of MMPs in interstitial lung disease (ILD) complicated with PM/DM (PM/DM-ILD).</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We retrospectively analysed serum levels of seven subsets of MMPs in 52 PM/DM-ILD patients diagnosed at Kyoto University Hospital or Tenri Hospital from January 2005 to December 2014. The patients were sub-grouped based on the presence of anti-amimoacyl-tRNA synthetase antibody (anti-ARS antibody), anti-melanoma differentiation-associated protein 5 antibody (anti-MDA5 antibody) or lack of the antibodies (ARS-ILD, MDA5-ILD and other-ILD groups, respectively) and independently analysed. Eighteen PM/DM patients without ILD and 55 healthy control were also analysed. Associations between serum levels of MMPs and clinical findings including mortality were analysed.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Among the MMPs analysed, MMP-7 serum levels in the ARS-ILD group were significantly higher compared with those in any of the other groups of PM/DM patients or in healthy controls. On the other hand, in the MDA5-ILD group, serum MMP-7 levels >5.08 ng/ml were associated with worse overall survival both in univariate (P = 0.017; odds ratio 18.0; 95% CI 1.69, 192.00) and multivariate (P = 0.027; odds ratio 14.60; 95% CI 1.11, 192.00) analyses. Immunohistochemical analysis suggested that MMP-7 was expressed in type II alveolar epithelial cells adjacent to the fibrotic lesions.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Serum MMP-7 levels were higher in anti-ARS antibody-positive PM/DM-ILD patients, while higher serum MMP-7 levels among anti-MDA5 antibody-positive PM/DM-ILD patients were associated with a worse prognosis. Fibrotic processes may be associated with the elevation of serum MMP-7 levels.</jats:p> </jats:sec>
収録刊行物
-
- Rheumatology
-
Rheumatology 58 (8), 1465-1473, 2019-03-08
Oxford University Press (OUP)